targovax

PLEASE JOIN US FOR OUR CAPITAL MARKETS DAY

With strong clinical data generated on ONCOS-102, Targovax is moving into late-stage clinical development. In addition, a broad pipeline of preclinical assets creates a broad horizon of opportunities in the future. Join our Capital Markets Day for more details!

DATEThursday, February 18, 2021TIME2:30 PM CETLOCATIONVirtual event with live streamingREPLAYAvailable after the event

KOL PARTICIPANT:

Alexander N. Shoushtari, MD Medical Oncologist, Memorial Sloan Kettering Cancer Center

Agenda & speakers

2:30-2:40 PM	Welcome	Øystein Soug, CEO, Targovax		
2:40-3:25 PM	Anti-PD1 refractory melanoma	Alexander N. Shoushtari, MD		
3:25-3:45 PM	ONCOS-102 development program	Magnus Jäderberg, MD CMO, Targovax		
5-minute break				
3:50-4:05 PM	Immune activation	Victor Levitsky, PhD, CSO, Targovax		
4:05-4:15 PM	Preclinical pipeline update	Victor Levitsky, PhD, CSO, Targovax		
4:15-4:25 PM	4Q update	Torbjørn Furuseth, MD, CFO, Targovax		
4:25 PM	Closing remarks	Øystein Soug, CEO, Targovax		

IMPORTANT NOTICE AND DISCLAIMER

This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in future and which, by their nature, will have an impact on the results of operations and the financial condition of Targovax. Such forward-looking statements reflect the current views of Targovax and are based on the information currently available to the company. Targovax cannot give any assurance as to the correctness of such statements.

There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the success of future clinical trials; risks relating to personal injury or death in connection with clinical trials or following commercialization of the company's products, and liability in connection therewith; risks relating to the company's freedom to operate (competitors patents) in respect of the products it develops; risks of non-approval of patents not yet granted and the company's ability to adequately protect its intellectual property and know-how; risks relating to obtaining regulatory approval and other regulatory risks relating to the development and future commercialization of the company's products; risks that research and development will not yield new products that achieve commercial success; risks relating to the future development of the pricing environment and/or regulations for pharmaceutical products; risks relating to the company's ability to secure additional financing in the future, which may not be available on favorable terms or at all; risks relating to currency fluctuations; risks associated with technological development, growth management, general economic and business conditions; risks relating to the company's ability to the company's negative to the impact of competition.



Welcome

- 2. Anti-PD1 refractory melanoma
- 3. ONCOS-102 development program
- 4. Immune activation
- 5. Preclinical pipeline update
- 6. 4Q update
- 7. Closing remarks



THE IMMUNO-ONCOLOGY REVOLUTION

> 500,000 patients treated per year
> 3,000 ongoing clinical trials
> 40% of US cancer patients eligible
> 10 approved products






FIRST GENERATION IMMUNO-ONCOLOGY: CHECKPOINT INHIBITORS

Cornerstone of current cancer treatment

Deep and durable responses


\$25b annual sales globally

7 products approved to date, many more in development



THE CHALLENGE:

MAKE PD1 CHECKPOINT INHIBITORS WORK FOR MORE PATIENTS



0-40% of treated patients respond


>50%

of responding patients relapse

PD-1 checkpoint inhibitor monotherapy not sufficient



THE SOLUTION: ONCOS-102 IMMUNE ACTIVATION



Activates the body's own T-cells against the cancer

Unblinds the tumor to the immune system

Reverses immunosuppressive defense mechanisms in the tumor


TARGOVAX AT A GLANCE



Lead product candidate

- Class-leading data in monotherapy and combinations with chemo and aPD-1
- o Powerful immune activation
- Ideal combination partner to aPD-1
- o Path to market

Vision: Unlock greater clinical benefits in cancer patients by deploying multifunctional platforms to target key immune regulators and oncogenic drivers



Pipeline

- Novel virus approaches
- Novel payloads and modes of action
- Mutant RAS cancer vaccine concepts

targovax

ONCOS-102


CLINICAL AND PRECLINICAL PIPELINE


Product candidate	Preclinical	Phase 1	Phase 2	Collaborator
	Melanoma Combination w/Keytruda			
ONCOS-102	Colorectal cancer Combination w/Imfinzi			AstraZeneca
	Mesothelioma Combination w/pemetrexed,	/cisplatin		
ONCOS-200 series	Next Gen viruses			leidos Papyrus
Novel mutRAS concepts				VALO THERAPEUTICS



EARLY-STAGE DEVELOPMENT SUCCESSFULLY COMPLETED – ENTERING LATE-STAGE DEVELOPMENT

Early-stage development







Late-stage development

PD1 refractory melanoma



Expansion opportunities

O Mesothelioma

O Colorectal cancer

• Other indications

- Other IO combinations
- Platform development



Product candidate	Preclinical	Phase 1	Phase 2	Collaborator	
ONCOS-102	Melanoma Combination w/Keytruda				
	Colorectal cancer Combination w/Imfinzi				



DR. ALEXANDER N. SHOUSHTARI, MEMORIAL SLOAN KETTERING CANCER CENTER



- Renowned expert in melanoma, with a research focus on checkpoint refractory melanomas
- Clinical Director and Assistant attending physician, Melanoma Services, Dept of Medicine, Memorial Sloan Kettering Cancer Center
- Principal investigator of several immunotherapy trials, including the ONCOS-102 phase I trial in CPI refractory advanced melanoma

